Dominic Smethurst - 14 Jan 2026 Form 4 Insider Report for Corbus Pharmaceuticals Holdings, Inc. (CRBP)

Reporting relationship: Chief Medical Officer
Issuer ticker: CRBP
Reported as of: 14 Jan 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 16 Jan 2026, 16:30:10 UTC
Prior SEC filing: 07 Mar 2025
Next SEC filing: 04 Feb 2026
Source filing: View source filing
Reporting owner signature: /s/ Meghan Houghton, Attorney-in-Fact for Dominic Smethurst

Key filing fact

Dominic Smethurst filed Form 4 for Corbus Pharmaceuticals Holdings, Inc. (CRBP) on 16 Jan 2026.

Key facts

This page summarizes Dominic Smethurst's Form 4 filing for Corbus Pharmaceuticals Holdings, Inc. (CRBP).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 16 Jan 2026, 16:30.

Change

Previous filing in this sequence was filed on 07 Mar 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001820549 Primary reporting owner

Smethurst Dominic

Relationship: Chief Medical Officer
Address: C/O CORBUS PHARMACEUTICALS HOLDINGS, INC, 500 RIVER RIDGE DRIVE, NORWOOD
Signature: /s/ Meghan Houghton, Attorney-in-Fact for Dominic Smethurst
Signature date: 16 Jan 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CRBP transaction

Common Stock, par value $0.0001 per share

Award

Transaction value: $0
Shares: +28,365
Change %: +40%
Price: $0.000000
Shares after: 99,172
Date: 14 Jan 2026
Ownership: Direct
Footnotes: F1, F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CRBP transaction Derivative

Stock options (right to buy)

Award

Transaction value: $0
Shares: +85,095
Change %
Price: $0.000000
Shares after: 85,095
Date: 14 Jan 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 85,095
Exercise price: $8.26
Footnotes: F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

On January 14, 2026, the Reporting Person was granted 28,365 restricted stock units ("RSUs"), which will be settled in shares of common stock, par value $0.0001. 25% of the RSUs shall vest on each of the first, second, third and fourth anniversary beginning on January 14, 2027. Notwithstanding the foregoing, upon termination of the Reporting Person's Service by the Company without cause, provided that such termination occurs after the first Vesting Date, then a pro rata portion of the RSUs shall accelerate in an amount equal to the product of (x) the number of RSUs scheduled to vest on the next Vesting Date and (y) a fraction, the numerator of which is the number of completed months of service the Awardee worked since the most recent Vesting Date through the date of Awardees termination of Service and the denominator of which is 12. The RSUs, to the extent not accelerated in accordance with this paragraph shall be forfeited upon such Reporting Person's termination of service.

Footnote F2

This amount includes 93,065 unvested RSUs subject to each grant's vesting schedule as previously reported.

Footnote F3

The annual option award was made in accordance with the terms of the issuer's 2024 Equity Compensation Plan. 25% of the option vests on January 14, 2027, with the remaining 75% of the option vesting in equal monthly installments over a period of 36 months commencing on February 14, 2027.